Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-830216
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMS-830216 is an investigational small molecule drug developed as a selective antagonist of the melanin-concentrating hormone receptor 1 (MCHR1). It is a thienopyrimidine derivative and acts as a prodrug for BMS‑819881. The compound was initially developed by Bristol Myers Squibb for the treatment of obesity, with its mechanism of action involving inhibition of MCHR1, which plays a role in energy homeostasis and body weight regulation. Clinical development reached Phase 1/2 trials in obese subjects to evaluate safety, pharmacokinetics, and pharmacodynamics[2][3][4].
- Other names
- BMS-819881 (active metabolite/prodrug relationship)
02
Targets
MCHR1 (Melanin-concentrating hormone receptor 1)
Beyond the preview
Go deeper on BMS-830216.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-830216.